GW Pharmaceuticals PLC- (NASDAQ:GWPH) shares gapped up prior to trading on Thursday . The stock had previously closed at $93.88, but opened at $93.94. GW Pharmaceuticals PLC- shares last traded at $95.48, with a volume of 277,847 shares changing hands.

A number of research analysts recently issued reports on GWPH shares. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $147.00 target price on shares of GW Pharmaceuticals PLC- in a research note on Friday, April 1st. Leerink Swann reiterated an “outperform” rating and issued a $130.00 target price on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, April 19th. Cantor Fitzgerald initiated coverage on shares of GW Pharmaceuticals PLC- in a research report on Thursday, June 2nd. They issued a “buy” rating and a $181.00 price target on the stock. Morgan Stanley restated a “buy” rating and issued a $149.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Friday, June 10th. Finally, Vetr lowered shares of GW Pharmaceuticals PLC- from a “strong-buy” rating to a “buy” rating and set a $87.65 price target on the stock. in a research report on Monday, May 16th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $127.47.

The stock’s 50-day moving average is $90.81 and its 200 day moving average is $72.21. The stock’s market capitalization is $2.05 billion.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.57) by $1.48. During the same period last year, the company posted ($0.03) earnings per share. The firm had revenue of $3.81 million for the quarter, compared to the consensus estimate of $5.99 million. The business’s revenue was down 58.3% compared to the same quarter last year. On average, analysts predict that GW Pharmaceuticals PLC- will post ($4.19) earnings per share for the current fiscal year.

An institutional investor recently raised its position in GW Pharmaceuticals PLC- stock. Trexquant Investment LP boosted its stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 188.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,719 shares of the biopharmaceutical company’s stock after buying an additional 15,509 shares during the period. Trexquant Investment LP owned approximately 0.11% of GW Pharmaceuticals PLC- worth $1,647,000 at the end of the most recent reporting period.

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.